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Abstract 
Background: No randomized study powered to compare balloon-expandable (BE) with 
self-expanding (SE) transcatheter heart valve (THV) on individual endpoints after transcatheter 
aortic valve replacement (TAVR) has been conducted to date.
Methods: From January 2013 to December 2015, the FRANCE-TAVI nationwide registry 
included 12,141 patients undergoing BE-THV (Edwards, n=8038) or SE-THV (Medtronic, 
n=4103) for native aortic stenosis (AS). Long-term mortality status was available in all patients 
(median 20 months, IQR:14-30). Patients treated with BE-THV (n=3910) were successfully 
matched 1:1 with 3910 patients treated with SE-THV by using propensity-score (25 clinical, 
anatomical and procedural variables) and by date of the procedure (within 3 months). The first 
co-primary outcome was the occurrence of paravalvular regurgitation (PVR)≥moderate and/or 
in-hospital mortality. The 2nd co-primary outcome was 2-year all-cause mortality. 
Results: In matched-propensity analyses, the incidence of the 1st co-primary outcome was 
higher with SE-THV (19.8%) compared with BE-THV(11.9%; RR=1.68; 95%CI:1.46-1.91; 
p<0.0001). Each component of the outcome was also higher in SE-THV patients: PVR≥moderate 
(15.5% vs. 8.3%; RR=1.90; 95% CI:1.63-2.22; p<0.0001) and in-hospital mortality (5.6% vs 
4.2%, RR=1.34; 95%CI:1.07-1.66; p=0.01). During follow-up, all-cause mortality occurred in 
899 patients treated with SE-THV (2-year mortality was 29.8%) and in 801 patients treated with 
BE-THV (2-year mortality 26.6%; HR=1.17; 95% CI:1.06-1.29; p=0.003). Similar results were 
found using inverse probability of treatment weighting using propensity score analysis. 
Conclusions: The present study suggests that use of SE-THV was associated with a higher risk 
of PVR and higher in-hospital and 2-year mortality as compared with BE-THV. These data 
strongly support the need for a randomized trial sufficiently powered to compare head‐to‐head 
the latest generation of SE and BE‐THV.(Registry of Aortic Valve Bioprostheses Established by 
Catheter [FRANCE-TAVI]; NCT01777828) 
Clinical Trial Registration: URL: https://clinicaltrials.gov Unique identifier: NCT01777828     
Key Words: Transcatheter aortic valve replacement; Transcatheter heart valve design; 
Paravalvular regurgitation; Clinical outcome; Mortality 
Abbreviations  
AR: aortic regurgitation 
AS: aortic stenosis 
BE: Balloon-expandable 
GEE: generalized estimating equations 
IPTW: inverse probability treatment weighting 
MDCT: multi-detector computed tomography 
PVR: Paravalvular regurgitation 
SAVR: surgical aortic valve replacement 
SE: self-expanding 
TAVR : transcatheter aortic valve replacement 
THV: transcatheter heart valve 
TTE: trans-thoracic echocardiography 
VARC-2: Valve Academic Research Consortium 2 
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Clinical Perspective 
What is new? 
• We compared the outcomes of the Balloon-expandable (BE) and self-expanding (SE)
transcatheter heart valves (THV) on a large nationwide registry (12,141 patients) after
propensity-matching on 25 major clinical and anatomical variables and on the time of the
procedure (within 3-months).
• SE-THV recipients had a higher risk of paravalvular regurgitation (PVR), mortality at 3
months and mortality at 2 years.
• The risk of mortality remained higher after multivariable adjustment including PVR
severity and of other peri-procedural events.
• This study suggests that the two most widely used THV designs may not achieve the
same clinical outcomes.
What are the clinical implications? 
• As TAVR is moving to be the first-line treatment for patients with aortic stenosis, this
study highlights:
• The urge for a randomized clinical study sufficiently powered to compare head-to-head
on individual endpoints the efficacy of the SE and BE-THV.
• The need to simplify and optimize the grading of PVR and its long term clinical impact.
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Introduction 
Over the last years, several randomized studies comparing transcatheter aortic valve replacement 
(TAVR) to surgical aortic valve replacement (SAVR) have established TAVR as a treatment 
option in symptomatic patients with aortic stenosis (AS) 1,2,3,4,5,6. 
Most transcatheter heart valves (THV) available are designed on either a balloon-
expandable (BE) or a self-expanding (SE) concept. Despite major differences, both designs are 
recommended to be used indifferently in most of the clinical situations. It remains unclear 
however, whether these 2 very different THV concepts are achieving similar or different clinical 
outcomes. While there is an urgent clinical need to clarify this issue in an exponentially growing 
therapeutic field, to date no large randomized study powered to compare the 2 THV designs on 
individual endpoints has been conducted or initiated. 
The occurrence of paravalvular regurgitation (PVR), in particular moderate or severe, has 
been associated with an increased long-term mortality risk7. Mild PVR have also been associated 
with higher mortality rate in some8, but not in all studies9. Small randomized studies10 and large 
registries11,12 have suggested that PVR≥moderate was more frequent with SE- than with BE-
THV. 
Recently, a large-scale registry suggested higher in-hospital mortality with the use of SE 
as compared to BE-THV13. Whether this difference persists over time is unclear as the excess 
mortality was no longer statistically significant by 30 days and as no long-term follow-up was 
conducted13. In addition, no information on PVR was available and no clear explanation was 
provided to elucidate the association observed in that study. 
FRANCE-TAVI is a nationwide registry collecting TAVR procedures performed in 
French TAVR centers and their follow-up12. The objective of this study was to evaluate the 
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impact of THV design (SE vs BE) on the risk of PVR, intra-hospital mortality, and 2-year 
mortality using a nationwide propensity score matched comparison. 
Methods 
FRANCE-TAVI registry and study population 
Because of the sensitive nature of the data collected for this study, reasonable requests to access 
the dataset from qualified researchers trained in human subject confidentiality protocols may be 
sent to the corresponding authors. 
Since January 2013, FRANCE-TAVI (NCT01777828) prospectively includes data for all 
patients who had undergone TAVR in 48 out of 50 TAVR centers in France and who 
volunteered to participate. This registry was designed in continuity with the FRANCE-2 
registry14,12 and is an initiative of the French Society of Cardiology and the French Working 
Group of Interventional Cardiology with the participation of the French Society of Thoracic and 
Cardiovascular Surgery. All patients included in the registry provided written informed consent 
before the procedure including consent for anonymous processing of their data. The registry was 
approved by the institutional review board of the French Ministry of Higher Education and 
Research (CCTIRS) and by the National Commission for Data Protection and Liberties (CNIL). 
For the purposes of the present analysis, a database encompassing all patients (n=12,804) 
included in the France-TAVI registry from January 2nd 2013 to December 31st 2015 was locked. 
Patients with a previous SAVR (n=559; including those referred for a valve-in-valve procdures) 
and those treated with a different THV-design (n=104; including Lotus-THV, Boston Scientific; 
Directflow-THV, DirectFlow Medical; JenaValve-THV, JenaValve Technology) were excluded Ac
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from the analysis to achieve a total number of 12,141 patients treated with SE(Medtronic) or 
BE(Edwards Lifesciences) THV-design (Supplemental Figure 1). 
Patient’s selection and TAVR procedure 
The decision to perform TAVR, choices of vascular approach and THV-design were based on a 
heart-team assessment at each participating center. Procedures and post-procedural management 
were performed in accordance with each site’s routine protocol. Thirty-day follow-up was 
recommended in the case-report form and performed either on-site or by telephone contact with 
the patient and their physician depending on each site’s protocol. Both commercially available 
valves were used: the BE–THV SAPIEN-XT (Jan. 2013-last quarter 2014) or SAPIEN 3 (last 
quarter 2014-Dec. 2015) valves (Edwards Lifesciences) and the SE-THV Corevalve valve 
(Medtronic). For each device, 4 sizes were available (BE-THV: 20, 23, 26 and 29 mm, and SE-
THV: 23, 26, 29 and 31mm). 
Pre-procedural sizing was performed using multi-detector computed tomography 
(MDCT) imaging. The technical aspects of the TAVR procedure have been previously reported 
in detail14,15.  
Evaluation of aortic regurgitation on Trans-Thoracic Echocardiography 
Pre-procedural trans-thoracic echocardiography (TTE) were performed in all patients and post-
procedural TTE was performed before hospital discharge with a median at day 3 (IQR=2-4). 
Pre-TAVR native aortic regurgitation (AR)16 and post-TAVR AR grading was site reported and 
not centrally adjudicated. AR grading was defined as “mild”, “moderate” or “severe” as 
described in France 211. The analysis was based on a multi-window, multi-parameter approach 
integrating the data of semi-quantitative and qualitative parameters, which include visual 
assessment of the number of jets, jet width, and the circumferential extent of PVR and evaluation 
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of regurgitant volume17, following the European and American Society of Echocardiography 
guidelines16,18 and Valve Academic Research Consortium(VARC)-2 recommendations19. 
Follow-up 
Mortality data was acquired in all patients from an INSEE(Institut national de la statistique et des 
études économiques) query on April 12th 2016, with dates of death available, with a median 
follow-up of 20 months (IQR=14-30). Deaths were classified as cardiovascular unless a clear 
non-cardiovascular cause was identified. Other follow-up adverse events, including re-
hospitalization, were site reported and assessed according to the VARC-2 classification19. 
Clinical Outcome 
Two co-primary outcomes were defined. The 1st co-primary outcome of the study was the 
assessment of PVR at discharge. Because PVR can only be evaluated in patients alive, this was 
achieved by defining “the occurrence of either PVR≥moderate on TTE before discharge or in-
hospital all-cause mortality” as estimate of PVR. The 2nd co-primary outcome of the study was 2-
year all-cause mortality. 
Secondary outcomes were: 1) each individual component of the 1st co-primary outcome, 
2) procedural and in-hospital events (requirement for a second THV, stroke, myocardial
infarction, major or life-threatening bleeding, major vascular complication, permanent 
pacemaker) and 3) post-procedural transprosthetic gradient by echocardiography. Follow-up 
events including hospitalization for acute cardiac event or for valve re-intervention, stroke, 
cardiovascular mortality and the composite of all-cause mortality, stroke or acute cardiac event 
were also reported. 
Data collection and management (see Supplemental appendix) Ac
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Statistical analysis 
Full details are available in Supplementary appendix. We assessed the effect of THV-design on 
short (PVR and/or intra-hospital all-cause mortality, mean and high residual gradient) and 2-year 
follow-up (all-cause and cardiovascular follow-up mortality, hospitalization for acute cardiac 
event or valve re-intervention) outcomes after taking into account the potential confounding 
factors by using pre-specified propensity-score methods20,21. As the primary analysis, propensity 
score was used to assemble well-balanced groups (propensity score-matched cohort) and, as a 
sensitivity analysis, propensity score was used to weight each subject by the inverse probability 
of treatment (stabilized inverse propensity score as weight) and generate an inverse probability 
treatment weighting (IPTW) cohort. Both analyses were performed to estimate the average 
treatment effect, namely the effect of treatment on the entire population eligible to TAVR. The 
propensity score was estimated using a non-parsimonious multivariable logistic regression 
model, with the THV-design (SE vs. BE) as the dependent variable and all of the baseline 
characteristics listed in Table 1 as the independent variables, since they were all considered 
potential confounders linked to clinical outcome. Patients treated with SE-THV were matched 
1:1 to patients treated with BE-THV according to date of procedure and propensity score using 
the greedy nearest neighbor matching algorithm according to a caliper width of 0·2 standard 
deviation of logit of propensity score and using the procedural date which should be within 3 
month of each other22,23. Because of missing baseline data (range 0-14%), leading to 24.5% of 
the study sample with at least 1 missing value among confounders included in propensity score 
calculation, treatment effect sizes were estimated using multiple imputation method. 
In propensity-score matched cohort, between-group comparisons (SE vs. BE-THV) were 
done using a generalized estimating equations (GEE) model (binomial distribution, log function) 
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with a compound symmetry working correlation structure for binary outcomes, a linear mixed 
model with the matched blocks as random effect for continuous, Fine and Gray (by treating death 
as competing risk) and Cox’s regression models for long-term outcomes with robust sandwich 
variance estimator to account the matched design. In IPTW cohort, comparisons were done using 
log-binomial (binary outcomes), linear mixed model (quantitative outcomes), Fine and Gray and 
Cox’s regression models (long-term outcomes), using the stabilized inverse propensity score as 
weight, and including the year of intervention as covariate. Propensity-score matched and IPTW 
analyses were adjusted for center, by including center as random effect in log-binomial and 
linear mixed models and as stratification factors in Cox’s and Fine and Gray models. We 
assessed the proportional hazard assumption using Schoenfeld residuals plots24; since the 
proportional hazard assumption was violated for all-cause and  cardiovascular mortalities, the 
treatment effect size was modeled using time-dependent coefficients25. We further investigated 
the heterogeneity in treatment effect size for the occurrence of PVR≥moderate (and/or in-
hospital all-cause mortality) across key subgroups. Finally, predictors of all-cause and 
cardiovascular mortalities were assessed using univariable and multivariable Cox’s regression 
models. Falsification outcomes, including mortality for malignancy and infection (individual or 
combined criteria), were post-hoc analysed to acknowledge possible residuals confounding 
related to the non-randomized controlled design. 
Statistical testing was conducted at the two-tailed α-level of 0·05. Data were analyzed using the 
SAS software version 9.3(SAS Institute). 
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Results 
Population 
From February 2013 to December 2015, a total of 12,141 patients with a severe native aortic 
stenosis were treated by TAVR in 48 centers and received either a BE-THV (n=8038) or a SE-
THV (n=4103) (Supplemental Figure 1). 
Baseline characteristics according to THV-design, before and after propensity score-
matching and after handling missing values by multiple imputation are presented in Table 1. 
Baseline characteristics before matching and handling missing values are presented in 
Supplemental Table 1. The distributions of propensity score according to THV-design are 
reported in Supplemental Figure 2. Before matching, most characteristics were already well 
balanced (absolute standardized difference ≤10%), except that patients treated with a BE-THV 
had a lower mean aortic annulus diameter, were more often treated in hybrid room, by femoral 
approach, and in the second study period (after January 2015) than patients treated by SE-THV. 
These differences were controlled after propensity-score matching (Table 1, Supplemental 
Figure 3) where 3910 matched pairs could be found. 
PVR and in-hospitality mortality according to BE- or SE-THV 
In the propensity-score matched cohort, post-procedural PVR≥moderate and/or in-hospital 
mortality occurred more frequently in patients treated with SE-THV (19.8%, n=776) than in 
patients treated with BE-THV (11.9%, n=466; matched-RR:1.68; 95% CI:1.47-1.91, Table 2). A 
similar difference was found in the IPTW cohort (RR:1.74; 95%CI:1.57-1.92, Table 2) as well as 
in the sensitivity analysis performed before handling missing outcome (i.e. on patients with 
available data on PVR status by TTE) with a matched- and IPTW-RRs of 1.66 (95%CI:1.46-
1.88) and 1.73 (95%CI:1.57-1.89) respectively. 
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Each component of the 1st co-primary outcome occurred more frequently in patients 
receiving the SE-THV. In the propensity-score matched cohort, PVR≥moderate was more 
frequent with SE- than BE-THV (15.5%, n=606; vs 8.3%, n=326; matched-RR=1.90; 
95%CI:1.63-2·22, Table 2).  In-hospital mortality was also higher in patients receiving a SE- 
than a BE-THV (5.6%, n=217; vs 4.2%, n=164; matched-RR=1.33; 95%CI:1.06-1.165, Table 2). 
A similar difference was observed in IPTW cohort (Table 2) as well as in sensitivity analysis 
performed before handling missing outcome with a matched- and IPTW-RR of 
1.88(95%CI:1.16-2.20) and 2.04 (95%CI:1·81-2·31), respectively. 
A similar difference was also observed when comparison was restricted to either older (before 
Sept. 2014) or newer (after Dec 2014) THV iterations (Supplemental Table 2 and 3). 
Among procedural and in-hospital events, implantation of a 2nd THV during the 
procedure and need of new pacemaker were more frequently observed in patients treated with a 
SE- than a BE-THV in the propensity-score matched and IPTW cohorts (p<0·0001 for both 
events, Table 2). Higher rates of stroke and myocardial infarction were also found in patients 
receiving a SE-THV in both propensity-score matched and IPTW cohorts, although difference in 
stroke did not reach the significance level (Table 2). Conversely, mean transprosthetic gradient 
(p<0.0001 for propensity-score-matched and IPTW cohorts) and rate of patients with a mean 
gradient>20 mmHg (p=0.17 for propensity-score-matched cohort and p=0.004 for IPTW cohort) 
were higher in patients receiving the BE-THV device. 
Two-year clinical outcome according to BE- or SE-THV-design 
During follow-up (median duration 20 months, IQR:14-30), 2390 patients died (including 1828 
from cardiovascular death, Supplemental Table 1).  In the propensity-score matched cohort, all-
cause mortality occurred in 899/3910 patients treated by SE-THV (24-month KM, 29·8%) and in 
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801/3910 patients treated by BE-THV (24-month KM, 26·6%), corresponding to a matched-HR 
of 1.17 (95%CI:1.06-1.28) (Figure 1 and Table 3; Supplemental Figure 4 for KM event curve in 
overall cohort before matching). However, proportional hazard assumption was not satisfied, 
since the excess mortality risk of SE-THV compared to BE-THV was only observed for the first-
3 months period (HR=1.37, 95%CI=1.16-1.60, Table 3). Similar results were found in IPTW 
cohort, with an HR associated with SE-THV of 1.38(95% CI:1.21-1.58) for 3-month mortality. 
When only cardiovascular mortality was considered, SE-THV remained associated with higher 
short-term mortality both in matched- and IPTW cohorts (Table 3). The incidence of reported 
hospitalization for acute cardiac event or valve intervention was also higher in patients receiving 
SE-THV versus BE-THV (Supplemental Table 4). 
Differences in clinical outcome persisted when comparisons were restricted to either 
older (before Sept. 2014) or newer (after Dec 2014) THV iterations (Supplemental Table 2 and 
3, Supplemental Figure 5). 
Subgroup analyses 
In the propensity-score matched cohort, the relation between the occurrence of the primary 
outcome and THV-design was consistent across key subgroups, except for delivery approach and 
study period, in which a significant interaction was observed (Figure 2A). 
The difference in the occurrence of the 1st co-primary outcome between SE-THV and 
BE-THV was stronger in patients treated via femoral approach (RR=1.82; 95%CI:1.56-2.13) 
than in those with a non-transfemoral access (RR=1.20; 95%CI:0.94-1.53, p for 
heterogeneity=0.004, Figure 2A). This was related to lower risk of events in patients treated via 
transfemoral as compared to non-transfemoral with a BE-THV (11.1% vs 15.1%) while the 
opposite was observed with a SE-THV(20.1% vs 17.6%). 
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The difference was also stronger in the second (≥01 January 2015, RR=2.23; 
95%CI:1.71-2·94) as compared to the first-study period (<01 January 2015, RR=1.48; 
95%CI:1.28-1.72; p for heterogeneity=0.006). This was related to a greater reduction of events 
between the first and second period in patients treated with BE-THV (14.3% vs. 7.9%) than in 
patients treated with SE-THV(21.0% vs. 18.0%). Similar heterogeneities were observed in IPTW 
cohort (Figure 2B, p for heterogeneity<0·001 for both). In addition, a significant heterogeneity 
across gender was found (p for heterogeneity=0.02), with a stronger THV-design difference in 
men (RR=1.92; 95%CI:1.68-2.19) than in women (RR=1.56; 95%CI:1.36-1.79). The same was 
true for the occurrence of a PVR≥moderate considered alone (Supplemental Figure 6). 
PVR and 2-year mortality 
As shown in Supplemental Table 5, PVR≥moderate was associated with a higher rate of 2-year 
all-cause and cardiovascular mortality, in the overall study population and in each THV-design. 
The other parameters associated with all-cause and cardiovascular mortalities by univariate 
analysis among baseline characteristics are presented in Supplemental Table 6. In multivariate 
analysis including univariate baseline predictors, both PVR severity and THV-design were 
independently associated with a higher risk of all-cause and cardiovascular mortality 
(Supplemental Table 7). 
Falsification outcomes 
Falsification outcomes (death from malignancy, death from infection or the composite of both) 
were observed at similar frequencies in patients treated with SE or BE-THV as observed in the 
propensity-score matched cohort and in the IPTW cohort (Supplemental Table 4). Ac
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Discussion 
The present propensity-score matched comparison of 7,820 patients with native AS undergoing 
TAVR based on the nationwide FRANCE-TAVI registry is the largest observational study to 
date comparing SE-THV and BE-THV on PVR and 2-year clinical outcome including mortality.  
This study, in which patients were carefully matched on 25 major clinical and anatomical 
variables and on the time of the procedure (within 3-months), reports that use of SE-THV was 
associated with higher risk of PVR, PVR and/or in-hospital mortality and 2-year mortality as 
compared with use of BE-THV. The association of THV type with 2-year mortality remained 
after multivariable adjustment including PVR severity and other peri-procedural events. 
THV-design and PVR 
This study, reporting on patients treated during the 2013-2015 period, demonstrates a higher 
incidence of PVR with SE- as compared to BE-THV, irrespective of valve generation. 
Anatomical and procedural characteristics were included in the propensity score, in particular 
aortic annulus diameter as measured by MDCT and the procedural route of delivery. The date of 
the procedure (within 3 months) was also incorporated in the matching process. As the study was 
running on a 3-year inclusion period, this allowed comparing each patient with a patient treated 
during the same time window (same valve generation, same level of expertise). Analyses 
restricted to the “older” period and to the “newer” period provided similar results with the main 
analysis (Supplemental Table 2 and 3, Supplemental Figure 5). 
These results of the period 2013-2015 are in line and confirm the observations made with 
the older generations of THV when optimal sizing using MDCT was not routinely implemented, 
in particular in the period 2010-2011 in the FRANCE-2 registry11 and in the period 2012-2013 in 
the CHOICE Study10. The higher incidence of PVR with SE-THV was observed in all subgroups 
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but the magnitude was stronger when the procedure was performed via femoral delivery (+88%) 
as previously observed11, and in those treated after January 2015 (+127%). The latter observation 
should be associated with the release during the last year of the study of the last generation of 
BE-THV (SAPIEN-3), featuring an anti-leak skirt, and of the newer generation of SE-THV. 
While the former allowed to decrease PVR rate from 9.2% to 6% compared with the previous 
years, the latter was not associated with a major impact on PVR (15.9% to 14.8%). Whether the 
newer iteration of SE-THV (Evolut-Pro) featuring an outer pericardial wrap will achieve to 
mitigate this major difference is unknown. A recent small non-randomized comparison did not 
show a significant difference in PVR rates between the two last iterations of SE-THV (Evolut vs 
Evolut-Pro)26.  
The remarkably low rate of PVR achieved in randomized clinical trials9,3 was not 
replicated in an all-comers real-life registry irrespective of THV design (PVR rate>5%). This 
could be related to different characteristics of randomized clinical trials which cannot be 
replicated in everyday practice such as the contribution of only high-volume expert centers, the 
use of centralized CT core laboratory valve sizing or the exclusion of patients when results are 
anticipated to be suboptimal. 
PVR and mortality 
PVR≥moderate has been consistently associated with higher short-term and long-term 
mortality27,14. Although it has been suggested that the severity of PVR in SE-THV recipients 
could decrease over time or that PVR anatomy and grading differs between SE- and BE-THV, 
the present study confirms that a PVR≥moderate as measured at 3 days is associated with a 
similar 40% additional risk of death for both BE- and SE-THV, suggesting that if PVR could 
regress, it does at a similar rate for both devices and/or that the timing and the magnitude is not 
Ac
ce
pte
d M
a
us
cri
pt
10.1161/CIRCULATIONAHA.119.043785 
16 
sufficient to impact mortality differently at 2-years. While there are discordant results regarding 
the role of mild or mild-to-moderate PVR on mortality27,28 , we observed that mild PVR was also 
associated with an additional risk of death (+13-18%). The potential deleterious long-term 
impact of mild PVR, which is observed in more than 30% in “low-risk” patients29,  will have to 
be further elucidated as the use of TAVR expands in this population. 
THV-design and mortality 
In the absence of head-to-head sufficiently-powered comparison the equipoise between the two 
THV designs is hypothetical. The small CHOICE10 and SOLVE-TAVI(NCT02737150) 
randomized non-inferiority trials did not report mortality difference, but included only a few 
hundreds of patients and were not powered to investigate mortality as primary endpoint. 
The present study demonstrates that the use of a SE-THV was associated with 16% higher risk of 
death at 2 years compared with the use of a BE-THV. This is explained by a 36% higher risk of 
death during the first 3 months with the 2 mortality curves remaining parallel after that period. 
These findings confirm the recent observation by the CENTER(Cerebrovacular-EvenNts-in-
Patients-Undergoing-TranscathetER-aortic-valve-implatation)-collaboration initiative of a higher 
in-hospital mortality with SE-THV compared to BE-THV13. However, in that study in which the 
latest follow-up was at 30 days, the mortality difference was no longer present at that time 
(p=0.10), and the authors concluded that “there was no difference in 30-day mortality rates 
between both valve types”. On the contrary, the present study, which is providing a much longer 
follow-up, demonstrates that the mortality difference observed between the 2 THV designs 
remains significant at 2 years (p=0.003). Ac
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The other limitations of the study by Vlastra include a very heterogeneous population 
originating from 10 different sources, the lack of information on PVR, and finally the lack of 
explanation for the “in-hospital mortality” finding which disappeared by 30 days. 
Our study suggests that part of the additional risk of death observed with SE-THV may 
relate to a higher risk of PVR, and also to a higher risk of in-hospital events, including stroke, 
myocardial infarction and pacemaker implantation. However, the additional mortality risk 
observed with SE-THV persists after adjustment on all baseline and procedural characteristics 
and all peri-procedural complications, including PVR, which is highly suggestive of direct and 
specific effect related to valve design. In addition, this observation, combined to the early 
separation of survival curves could also suggest that PVR is partly acting as a marker rather than 
being the main driver of the mortality difference between the 2 THV designs. More granular 
registry data are needed to identify the parameters associated with higher mortality risk, such as 
occurrence and type of conduction disorders, valve calcium score, prosthesis hemodynamics, left 
ventricular dimensions, valve thrombosis, delayed coronary events. 
Even if designs and clinical endpoints may have been slightly different between the 
landmarks trials evaluating BE-THV or SE-THV vs SAVR; transfemoral BE-THV was 
consistently superior to SAVR in high2, intermediate9 and low risk5 patients whereas SE-THV 
achieved only superiority to SAVR in high-risk patients3,4,6. Our study sheds fresh light on these 
previous results and suggests that TAVR study findings should not be generalized as a class-
effect regardless of the SE or BE-THV design. 
Limitations 
Observational registries are the only way to capture all-comers data on a national scale, but 
several limitations should be considered when interpreting the results. PVR grading are site-
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reported and were not analyzed in a core laboratory, which may have resulted in potential 
reporting bias and heterogeneity in PVR grading among centers. Clinical events, including re-
hospitalization are site-reported and not adjudicated, therefore exposing to the risk of under-
reporting. However, mortality data are complete are they are obtained from an INSEE query. 
Furthermore, there is no reason to believe that under-reporting by the sites of some clinical 
events would differ according to type of THV.  In addition, the lack of difference in PVR 
severity among centers once adjusted to the type of THV does not support presence of 
heterogeneity in PVR grading. This issue was further taken into account in multivariable 
analyses of predictors of PVR where adjustment for “participating centers” was done which 
reinforce interpretation of the main finding of this study. 
It is not a randomized trial and potential differences in unmeasured variables might 
remain despite the risk-adjustment matching process. Among others the presence of extensive 
valve calcification, massively calcified aortic root, or small femoral vessel size were not 
measured and could be more frequent in patients receiving a SE-THV. Such residual 
confounders could explain all or part of the mortality difference. However, the baseline clinical, 
anatomical and procedural characteristics of this very large cohort were already well balanced 
between the 2 populations (Table 1).  The propensity-score matching process involving>25 
variables was able to further “balance” the very few variables which were not, in particular aortic 
annulus diameter and delivery approach. Further, the analysis of falsification endpoints found no 
signs of a hidden bias exaggerating the mortality difference observed between the 2 THV groups. 
Similar methodology using registry data and propensity-score analysis has previously been 
highly predictive of the results of randomized studies, as in the study by Thourani et al.30 Ac
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predicting accurately the results of the PARTNER-2 study9, or in the study by Makkar et al.31 
investigating the use of TAVR in patient with bicuspid vs tricuspid aortic stenosis. 
It remains to be demonstrated whether the differences observed in the present study 
would still stand whether comparing the newer SE-THV (Evolut-Pro) to the SAPIEN-3. While 
the Evolut-Pro does not appear to be associated with a significantly lower risk of PVR compared 
to previous iterations of SE-THV25, on multivariable analysis the significant difference between 
BE-THV and SE-THV with respect to mortality persisted despite comprehensive adjustment for 
several factors including PVR (Supplemental Table 7). Finally, the 4 THVs iterations 
(Corevalve, Evolut, SAPIEN-XT, SAPIEN-3) investigated in the present study are also those 
used in the randomized studies investigating the benefit of TAVR vs SAVR, including the most 
recent ones. In particular, the SAPIEN-3 was the BE-THV used in all patient undergoing TAVR 
in PARTNER 35, while the Corevalve and Evolut were used in the vast majority (80%) of 
patients undergoing TAVR in the “Evolut Low Risk Study”6, the other 20% receiving the 
Evolut-Pro. 
Conclusion and clinical perspective 
The present study suggests important differences in clinical outcome according to THV design, 
as use of SE-THV was associated with a higher risk of all-cause mortality at 2 years as compared 
with BE-THV. However, as the propensity-score matching-approach cannot rule out residual 
confounders, and as some of the most recent THV iterations were not part of the investigation, 
there is an urgent need to conduct a randomized trial sufficiently powered to compare 
head-to-head the latest generation of SE- and BE-THV on all-cause mortality. The present results 
also strengthen the need to refine the identification and grading of PVR and its long-term clinical 
impact31,32. 
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Table 1. Baseline Characteristics According to SE- or BE-THV Design Before and After Matching. 
Before Matching * After Matching *† 
Characteristics SE-THV 
(n=4103) 
BE-THV 
(n=8038) 
ASD, % SE-THV 
(n=3910) 
BE-THV 
(n=3910) 
ASD, % 
Clinical characteristics 
Age, y mean ± SD 83.5 ± 7.0 83.5 ± 7.1 0.4 83.5 ± 7.1 83.5 ± 9.0 0.5 
Men 2027 (49.4) 3939 (49.0) 0.8 1922 (49.2) 1908 (48.8) 0.6 
NYHA class 
I 210 (5.1) 325 (4.1) 7.8 189 (4.8) 161 (4.2) 7.5 
II 1210 (29.5) 2232 (27.8) 1161 (29.7) 1099 (28.1) 
II 2257 (55.0) 4698 (58.4) 2152 (55.0) 2295 (58.7) 
IV 426 (10.4) 783 (9.7) 408 (10.4) 355 (9.1) 
Log.EuroSCORE, median (IQR) 14.0 (9.0 to 22.5) 15.0 (9.6 to 23.0) 5.8‡ 14.0 (9.0 to 22.6) 15.0 (9.6 to 22.2) 4.1‡ 
High operative risk 1509 (36.8) 3193 (39.7) 6.1 1451 (37.1) 1471 (37.6) 1.1 
BMI, kg/m2, mean ± SD 26.5 ± 5.4 26.5 ± 5.3 0.6 26.5 ± 5.4 26.5 ± 6.6 0.5 
Diabetes mellitus 1065 (25.9) 2106 (26.2) 0.6 1016 (26.0) 997 (25.5) 0.9 
Hypertension 2722 (66.3) 5439 (67.8) 2.8 2604 (66.6) 2603 (66.6) 0.1 
CAD 1830 (44.6) 3401 (42.3) 4.6 1724 (44.1) 1764 (45.1) 1.8 
Previous stroke or TIA 467 (11.4) 873 (10.9) 1.6 444 (11.4) 441 (11.3) 0.1 
PAD 965 (23.5) 1814 (22.6) 2.3 914 (23.4) 899 (23.0) 0.7 
Atrial fibrillation 1016 (24.8) 1997 (24.8) 0.2 973 (24.9) 983 (25.2) 0.7 
Permanent pacemaker 629 (15.3) 1093 (13.6) 4.9 586 (15.0) 607 (15.5) 1.3 
Previous CABG 464 (11.3) 857 (10.7) 2.1 437 (11.2) 459 (11.8) 1.7 
Respiratory insufficiency 871 (21.2) 1592 (19.8) 3.5 812 (20.8) 846 (21.6) 1.8 
Renal insufficiency|| 210 (5.1) 421 (5.2) 0.5 197 (5.1) 206 (5.3) 0.7 
Pre-procedural imaging 
Aortic annulus diameter, mm, mean± SD 24.2 ± 2.8 23.5 ± 2.7 27.9 24.1 ± 2.7 24.0 ± 2.7 2.2 
LVEF, %, mean (SD) 54.7 ± 13.7 55.5 ± 13.7 5.6 54.9 ± 14.0 54.7 ± 15.3 1.9 
<30% 186 (4.5) 334 (4.2) 4.6 170 (4.4) 185 (4.8) 1.9 
30% to 49% 991 (24.1) 1805 (22.5) 926 (23.7) 931 (23.8) 
≥50% 2926 (71.3) 5898 (73.4) 2814 (72.0) 2794 (71.5) 
AVA, cm2, median (IQR) 0.7 (0.5 to 0.8) 0.7 (0.5 to 0.8) 0.5‡ 0.7 (0.5 to 0.8) 0.7 (0.5 to 0.8) 0.3‡ 
Trans-aortic gradient, mmHg, mean ± SD 47.1 ± 16.0 47.6 ± 16.0 2.8 47.3 ± 16.1) 47.2 ± 18.0 0.5 Ac
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AR grade≥2 871 (21.2) 1442 (17.9) 8.3 798 (20.4) 825 (21.1) 1.6 
MR grade≥2 941 (22.9) 1776 (22.1) 2.0 888 (22.7) 884 (22.6) 0.3 
Procedural characteristics 
Room of intervention 
  Catheterization laboratory 1607 (39.2) 2681 (33.4) 13.7 1501 (38.4) 1472 (37.7) 2.9 
  Hybrid Room 2343 (57.1) 4917 (61.2) 2260 (57.8) 2267 (58.0) 
  Operating Room 154 (3.7) 440 (5.5) 149 (3.8) 171 (4.4) 
General anesthesia 2166 (52.8) 4085 (50.8) 3.9 2037 (52.1) 2111 (54.0) 3.4 
Transfemoral approach 3287 (80.1) 6754 (84.0) 10.2 3183 (81.4) 3130 (80.1) 3.1 
Years of intervention 
January 2013 to December 2014 2619 (63.8) 4123 (51.3) 25.6 1470 (37.6) 1475 (37.8) 0.3 
January 2015 to December 2015 1484 (36.2) 3915 (48.7) 2440 (62.4) 2435 (62.3) 
Values expressed as numbers (%) unless otherwise indicated. *calculated after handling missing data using multiple imputation procedure (m=10). 
†matching on propensity score and date of TAVR procedure (± 3 month). ‡estimated using the rank-transformed data. ||serum creatinine >200 µmol/L. 
Abbreviations: AR=aortic regurgitation; ASD=Absolute standardized difference; AVA=aortic valve area; BE=Balloon-expandable; BMI=body mass 
index; CABG=coronary artery bypass grafting; CAD=coronary artery disease; LEVF=left ventricular ejection fraction; MR=mitral regurgitation; 
NYHA=New York Heart Association; PAD=peripheral arterial disease; SD=standard deviation; SE=self-expanding; TIA=transient ischemic attack; 
TTE=transthoracic echocardiography. 
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Table 2. Paravalvular Regurgitation, Intra-hospital Mortality and Other Procedural and in-hospital Clinical 
Events According to SE- or BE-THV Design in Propensity-Score Matched and IPTW Cohorts. 
Outcomes SE-THV BE-THV Effect size (95%CI) P-Value 
Propensity-Score Matched Cohort N=3910 N=3910 
PVR≥moderate and/or Intra-hospital mortality* 776 (19.8) 466 (11.9) 1.68 (1.47 to 1.91)† <0.0001 
PVR≥moderate 606 (15.5) 326 (8.3) 1.90 (1.63 to 2.22)† <0.0001 
Intra-hospital mortality 217 (5.6) 164 (4.2) 1.33 (1.06 to 1.65)† 0.01 
Other procedural and intra-hospital events 
Second THV 143 (3.7) 38 (1.0) 3.79 (2.40 to 5.99)† <0.0001 
Stroke 96 (2.5) 70 (1.8) 1.38 (0.98 to 1.94)† 0.058 
Myocardial infarction‡ 14 (0.4) 7 (0.2) 2.07 (1.11 to 3.88)† 0.02 
Major or life-threatening bleeding 398 (10.2) 356 (9.1) 1.03 (0.89 to 1.19)† 0.68 
Major vascular complication 292 (7.5) 270 (6.9) 1.02 (0.85 to 1.22)† 0.81 
Permanent pacemaker implantation 871 (22.3) 431 (11.0) 2.08 (1.83 to 2.35)† <0.0001 
Post-procedural transprosthetic echocardiography gradient 
Mean gradient (median, IQR) 7 (5 to 10) 10 (7 o 13) -0.21 (-0.24 to -0.19)|| <0.0001 
Mean gradient>20 mmHg 75 (1.9) 102 (2.6) 0.75 (0.48 to 1.16)|| 0.17 
IPTW Cohort N=4103 N=8038 
PVR≥moderate and/or Intra-hospital mortality* 817 (19.9) 871 (10.8) 1.74 (1.57 to 1.92)# <0.0001 
PVR≥moderate 640 (15.6) 605 (7.5) 2.05 (1.80 to 2.33)# <0.0001 
Intra-hospital mortality 229 (5.6) 307 (3.8) 1.33 (1.12 to 1.58 # 0.001 
Other procedural and Intra-hospital events 
     Second THV implantation 151 (3.7) 66 (0.8) 4.26 (3.18 to 5.71 # <0.0001 
Stroke 99 (2.4) 143 (1.8) 1.31 (0.99 to 1.71)# 0.051 
Myocardial infarction‡ 15 (0.4) 11 (0.1) 2.51 (1.14 to 5.46)# 0.02 
Major or life-treating bleeding 418 (10.2) 651 (8.1) 1.10 (0.97 to 1.24)# 0.13 
Vascular complications 299 (7.3) 518 (6.4) 0.98 (0.84 to 1.13)# 0.74 
Permanent pacemaker implantation 903 (22.0) 895 (11.1) 2.06 (1.88 to 2.25)# <0.0001 
Post-procedural transprosthetic echocardiography gradient 
Mean gradient (median, IQR) 7 (5 to 10) 10 (7 to 13) -0.23 (-0.25 to -0.21)** <0.001 
Mean gradient>20 mmHg 79 (1.9) 245 (3.1) 0.65 (0.49 to 0.88)** 0.004 
Values are n(%) or median (IQR). Effect sizes are relative risk or mean difference (loge) in mean transprothetic 
gradient calculated using BE-THV as reference group. 
*pre-specified as 1st co-primary outcome. †calculated using a GEE model for binary data with a log link function
to account the matched sets and including center as random effect. ‡ST-elevation myocardial infarction related to 
acute coronary obstruction. ||calculated using a linear mixed model (on log-transformed data) including matched 
sets and center as random effects. #calculated using a log-binomial regression model weighted by inverse 
probability of treatment using propensity score, including center as random effect and year of intervention as 
fixed effect. **calculated using a linear mixed model (on log-transformed data) weighted by inverse probability of 
treatment using propensity score, including center as random effect and year of intervention as fixed effect.  
Values and effect sizes were calculated after handling missing values for variables included in the propensity 
score and outcomes by multiple imputation.  
Abbreviations: AR=aortic regurgitation, BE=balloon-expandable, CI=confidence intervals, GEE=Generalized 
Estimating Equations, IPTW=inverse probability of treatment weighting, SE=self-expanding. 
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Table 3. Follow-up 2-year Mortality according to the SE- vs BE-THV-design In Propensity-Score Matched 
and IPTW Cohorts. 
Outcomes SE-THV BE-THV HR (95%CI) P-Value 
Propensity-Score Matched Cohort N=3910 N=3910 
Follow-up all-cause mortality 899 (29.8) 801 (26.6) 1.17 (1.06 to 1.28)* 0.002 
0 to 3 months 381 286 1.37 (1.16 to 1.60)* 0.0001 
3 to 6 months 104 92 1.23 (0.88 to 1.70)* 0.22 
6 month to end of follow-up 414 423 1.00 (0.85 to 1.18)* 0.89 
Follow-up cardiovascular mortality 675 (23.3) 612 (20.9) 1.18 (1.03 to 1.32)* 0.001 
0 to 3 months 270 192 1.47 (1.19 to 1.82)* 0.0004 
3 to 6 months 77 77 1.15 (0.80 to 1.65)* 0.44 
6 month to end of follow-up 328 343 1.01 (0.82 to 1.20)* 0.86 
IPTW Cohort N=4103 N=8038 
Follow-up all-cause mortality 958 (29.9) 1432 (25.7) 1.18 (1.08 to 1.29)† <0.0001 
0 to 3 months 402 541 1.38 (1.21 to 1.58)† <0.0001 
3 to 6 months 112 183 1.21 (0.93 to 1.56)† 0.19 
6 month to end of follow-up 444 708 1.03 (0.90 to 1.17)† 0.66 
Follow-up cardiovascular mortality 721 (23.4) 1107 (20.5) 1.19 (1.05 to 1.34)† 0.001 
0 to 3 months 286 374 1.46 (1.24 to 1.73)† <0.0001 
3 to 6 months 84 155 1.14 (0.85 to 1.53)† 0.37 
    6 month to end of follow-up 351 578 1.00 (0.86 to 1.5)† 0.88 
Values in brackets in columns 2 and 3 are cumulative incidence at 2-year expresses as % (calculated using 
Kalbfleisch and Prentice for follow-up hospitalizations by treating death as competing risk, or using Kaplan-
Meier method for mortality) * calculated using a Fine and Gray or Cox’s regression model stratified by center 
with the robust sandwich variance estimate to account the matched sets. † calculated using a Fine and Gray or 
Cox’s regression model stratified by center, weighted by inverse probability of treatment using propensity 
score and including year of intervention as covariable. Number of events, cumulative incidence and HRs were 
calculated after handling missing values for variables included in the propensity score by multiple imputation. 
Abbreviations: BE=balloon-expandable, CI=confidence intervals, HR=hazard ratio, IPTW=inverse probability 
of treatment weighting, SE=self-expanding. 
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Figure Legends 
Figure 1. Kaplan-Meier Curves of All-cause Mortality (A) and Cardiovascular Mortality 
(B) According to SE- vs BE-THV design in Matched-propensity score cohort. 
Kaplan-Meier estimates and number of patients at risk were calculated after handling missing 
values for variables included in the propensity score by multiple imputation (using a 
complementary log-log as normalizing transformation for survival probabilities). 
Figure 2. Comparisons of the occurrence of the 1st co-Primary Outcome (PVR≥moderate 
and/or in-hospital mortality) Between SE- and BE-THV design according to key subgroups 
In Propensity-Score Matched (A) and IPTW (B) Cohorts. 
Panel A: RRs were calculated using a GEE model for binary data (with a log link function) to 
account the matched sets and after adjustment for center (random effect). P het indicates p-value 
for heterogeneity. Number of events (%), and RRs were calculated after handling missing values 
for variables included in the propensity score by multiple imputation. Abbreviations: AR=aortic 
regurgitation, BE=balloon-expandable, CI=confidence intervals, GEE=Generalized Estimating 
Equations, MR=mitral regurgitation, RR=relative risk, SE=self-expanding. 
Panel B: RRs were calculated using a binary log-binomial regression model before and after 
inverse probability of treatment weighting using propensity score, adjustment for center (random 
effect) and year of intervention (fixed effects). P het indicates p-value for heterogeneity. Number 
of events (%), and RRs were calculated after handling missing values for variables included in 
the propensity score by multiple imputation. Abbreviations: AR=aortic regurgitation, Ac
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BE=balloon-expandable, CI=confidence intervals, IPTW: Inverse probability of treatment 
weighting, MR=mitral regurgitation, RR=relative risk, SE=self-expanding. 
Ac
ce
pte
d M
an
us
cri
pt
A)
B)
Ac
ce
pte
d M
an
us
cri
pt
A)
Ac
ce
pte
d M
an
us
cri
pt
B)
Ac
ce
pte
d M
an
us
cri
pt
